Jkb-122    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
95Autoimmune hepatitis3

95. Autoimmune hepatitis    [ 44 clinical trials,   57 drugs,   (DrugBank: 26 drugs),   18 drug target genes,   108 drug target pathways]
Searched query = "Autoimmune hepatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 44 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04371718
(ClinicalTrials.gov)
November 202029/4/2020Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)A Phase II, Randomized, Double-Blind, Placebo Controlled, Trial of JKB-122 as an Adjunct Therapy to Prednisolone and Azathioprine in the Induction of Remission in Autoimmune Hepatitis (AIH)Autoimmune HepatitisDrug: JKB-122;Other: PlaceboTaiwanJ Pharmaceuticals Co., LtdNULLNot yet recruiting18 Years65 YearsAll120Phase 2NULL
2NCT04313205
(ClinicalTrials.gov)
August 202016/3/2020A Pharmacokinetic Study of JKB-122 Tablets Compared to CapsuleA Randomized, Open-label, Multiple-dose, Two-period, Crossover, Study to Investigate the Pharmacokinetic Profile of 2 Formulations of JKB-122 in Healthy Male SubjectsAutoimmune HepatitisDrug: JKB-122 in capsule or tablet formTaiwanJ Pharmaceuticals Co., LtdNULLNot yet recruiting20 Years45 YearsMale8Phase 1NULL
3NCT02556372
(ClinicalTrials.gov)
April 30, 201620/9/2015Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current TherapiesA Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current TherapiesAutoimmune HepatitisDrug: JKB-122TaiwanJ Pharmaceuticals Co., LtdNULLCompleted18 YearsN/AAll20Phase 2United States